BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29710846)

  • 1. Anti-Proliferative Activity of HPOB against Multiple Myeloma Cells via p21 Transcriptional Activation.
    Liu L; Sun X; Xie Y; Zhuang Y; Yao R; Xu K
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29710846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
    Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Yao R; Xu K
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30782785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21.
    Yao R; Han D; Sun X; Xie Y; Wu Q; Fu C; Yao Y; Li H; Li Z; Xu K
    Exp Hematol; 2018 Apr; 60():63-72. PubMed ID: 29305109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].
    Ma J; Zhao M; Yu XD; Wang ZH
    Ai Zheng; 2009 May; 28(5):466-71. PubMed ID: 19624872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
    Wang B; Lyu H; Pei S; Song D; Ni J; Liu B
    Cell Cycle; 2018; 17(8):985-996. PubMed ID: 29969371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
    Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
    Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH; Zhang PR; Cai PY; Li ZC
    Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
    Kim B; Kim SH; Jeong SJ; Sohn EJ; Jung JH; Lee MH; Kim SH
    J Agric Food Chem; 2012 Oct; 60(39):9882-9. PubMed ID: 22967175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
    Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
    Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
    Hecker RM; Amstutz RA; Wachtel M; Walter D; Niggli FK; Schäfer BW
    Oncogene; 2010 Jul; 29(27):3942-52. PubMed ID: 20453878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
    Hao ZF; Su YM; Wang CM; Yang RY
    Tumour Biol; 2015 Mar; 36(3):1471-6. PubMed ID: 25371069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.